Quality of life by smoking status in patients with metastatic or advanced NSCLC from Phase 2 clinical trial of veliparib with carboplatin and paclitaxel.

Authors:

Abstract
E20549 Background: A Phase 2 clinical trial of veliparib + carboplatin (C) and paclitaxel (P) in patients (pts) with previously untreated metastatic/advanced NSCLC showed that veliparib may improve survival compared to placebo and that smoking history was a strong predictor of efficacy for veliparib+CP. This study compares quality of life (QoL) by smoking status in pts receiving veliparib+CP vs placebo+CP. Methods: This study is a secondary analysis of a Phase 2 clinical trial (NCT01560104) where pts were randomized 2:1 to veliparib+CP (120mg BID) or placebo+CP for up to 6 treatment cycles (study period). Pts with ≥ 1 QoL measurement at baseline (pre-treatment initiation) and during ≥ 1 cycle were selected and stratified by smoking status in the year preceding the trial (smokers [S] vs non-smokers [NS]). Proportions of pts with a QoL improvement (QoL+)/deterioration (QoL-) from baseline achieving minimal important difference ( ≥ 10 points on a 100-point scale) across the study period were compared by treatment and smoking status using generalized estimating equation models adjusted for baseline QoL score, gender, and ECOG, for each of the 22 EORTC QLQ-C15-PAL/LC13 questionnaire items. Results: Among 143 pts (657 pt-cycles), mean age was 62 years, 67% were male, and 59% were S. In S, veliparib+CP pts had better or non-different QoL compared to placebo+CP pts; a higher proportion of veliparib+CP pts had QoL+ for dyspnea (odds ratio [OR] = 3.63) and a lower proportion of pts had QoL- for physical functioning (OR = 0.46), appetite loss (OR = 0.37), and dysphagia (OR = 0.12), all p < .05. In veliparib+CP pts, S had better or non-different QoL compared to NS (emotional functioning: both QoL+ and QoL- OR = 2.80 and 0.38, respectively; pain in chest: QoL+ OR = 3.86; coughing: QoL- OR = 0.48; all p < .05). The magnitude of the difference in QoL for S vs NS was larger or non-different in veliparib+CP pts compared to placebo+CP pts (dyspnea: QoL+ OR = 8.48; appetite loss: QoL+ OR = 11.54, QoL- OR = 0.27; dysphagia: QoL- OR = 0.05; all p < .05). Conclusions: Smokers receiving veliparib+CP had better or non-different QoL compared to both non-smokers receiving veliparib+CP and to smokers receiving placebo+CP. Clinical trial information: NCT01560104.